Real-world data on immunotherapy combined with chemotherapy in elderly patients with extensive-stage small cell lung cancer
Abstract Background Immunotherapy combined with chemotherapy has shown good results in the treatment of extensive-stage small cell lung cancer (ES-SCLC), but there are fewer clinical studies on elderly ES-SCLC patients. This study was aimed to evaluate the efficacy and safety of immunotherapy in com...
Saved in:
| Main Authors: | Ke Zhao, Shuangqing Lu, Jiling Niu, Hui Zhu, Yaru Tian, Jinming Yu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-03-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-13880-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Camrelizumab, an Anti‐PD‐1 Monoclonal Antibody, Plus Carboplatin and Nab‐Paclitaxel as First‐Line Setting for Extensive‐Stage Small‐Cell Lung Cancer: A Phase 2 Trial and Biomarker Analysis
by: Jia Yu, et al.
Published: (2025-08-01) -
Efficacy and safety of first-line chemotherapy combined with immune checkpoint inhibitors for extensive-stage small cell lung cancer patients: a real-world propensity score matching study
by: Bin Jia, et al.
Published: (2025-08-01) -
Efficacy of PD-(L)1 inhibitors plus anlotinib in the second-line treatment of extensive-stage small cell lung cancer
by: Jian Zhang, et al.
Published: (2025-07-01) -
Molecular subtyping dictates therapeutic response to anti-PD-L1 immunotherapy in ES-SCLC
by: Qianqian Zhang, et al.
Published: (2025-05-01) -
Feasibility and Safety of Anlotinib Combined with Immune Checkpoint Inhibitors in Patients with Previously Immunotherapy-Treated Extensive-Stage Small Cell Lung Cancer: A Retrospective Exploratory Study
by: Chen TF, et al.
Published: (2025-06-01)